Januvia Pancreas Injury

Januvia (Sitagliptin) is a type 2 diabetes medication in the class of GLP-1 mimicking (incretin) type 2 diabetes drugs.

It is linked to precancerous and cancerous changes in the pancreas. Although Januvia and fellow GLP-1mimicking drugs Byetta and Victoza were prescribed over 33 million times, the FDA has not banned them. Our firm helps those people who have been hurt through no fault of their own after using Januvia.

What Is Januvia?

Januvia is the trade name under which Merck & Co. marketed and sold Sitagliptin. It was approved by the U.S. FDA for treatment of type 2 diabetes on October 17, 2006.

Januvia is designed as a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes. The benefit of this drug was stated to be fewer adverse side effects. It is administered orally through a 100 mg tablet which is beige, round, film-coated with “277” on one side; through a 50 mg tablet which is light beige, round, film-coated with “112” on one side”; or through a 25 mg tablet which is pink, round, film-coated and with “221” on one side.​

How Can Januvia Harm You?

Currently known risks include Pancreatitis, Renal Impairment (including Acute Renal Failure), and Pancreatic Cancer. People who are hypersensitive may also experience skin conditions such as Anaphylaxis, Angioderma and Stevens-Johnson syndrome.​

How Can We Help?

The Madeksho Law Firm, PLLC will shoulder the burden of taking on the pharmaceutical industry on behalf of our clients just like it has taken on corporate wrongdoers for over 40 years. If you are prescribed a drug, it should be made safe by adequate warning, adequate research or adequate design. If a drug carries risks, the drug manufacturer should be honest about what those risks are. Call our attorneys today for a free legal consultation and we will explain your rights and how we can help. Attorneys at the Madeksho Law Firm, PLLC will do our duty to keep you informed and protected in a professional, compassionate manner.​